Search Medical Condition
Please enter condition
Please choose location from dropdown

COVID-19 Clinical Trials

A listing of COVID-19 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found (718) clinical trials

Will Hydroxychloroquine Impede or Prevent COVID-19

The study will randomize a total of 3,000 HCW, NHW, FR and DDOT bus drivers within Henry Ford Hospital System, the Detroit COVID Consortium in Southeast, Michigan. The participants will be randomized in a 1:1:1 blinded comparison of daily HCQ, weekly HCQ, or placebo. A fourth non-randomized comparator group of …


The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients

The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has …


SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Using a proprietary application programming interface (API) linked to existing electronic health …

Phase N/A

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

This is a phase 3 study. Primary Objective: To evaluate clinical outcomes in patients with suspected or confirmed COVID-19 with early moderate to severe disease in a randomized controlled trial. Secondary Objectives: To evaluate quantitative viral load over time To evaluate length of hospital stay and days in ICU To …


Impact of COVID19 Outbreak in Cardiac Acute Care

Registry on Characteristics and outcomes of Cardiac patients (COVID- and COVID+) hospitalized in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France

Phase N/A

DIgital Online SuPport for COVID-19 StrEss

The overall aim of this randomised trial with observational component is to estimate the effects of a guided digital online support program to increase mental health and reduce psychosocial stress in the context of the COVID-19 pandemic. More specifically, the main hypothesis is to estimate whether the improvement in mental …

Phase N/A

Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2) COVID-19 Causative Agent.

The outbreak of COVID-19 infections is spreading in Italy with unprecedented severity characteristics. In this context, it is essential to collect data relating to the epidemiology of the disease, to outline further useful tools for diagnosis and to define the correct use of rapid molecular and / or serological tests …

Phase N/A

Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19

This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.

Phase N/A

Oropharyngeal Dysphagia in Patients With COVID-19

Background Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute …

Phase N/A

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Overall study design This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first. Interim analysis will be permitted as …